TABLE 2.
Local Changes in Soluble Factor Expression in Pancreatic Tissue or Pancreatic Juice From CP Patients Compared to Healthy Controls
| Factor | Expression Change in CP | Reference | Source | |||
|---|---|---|---|---|---|---|
| IL-6 | + | + | = | = | 69, 70, 71, 25 | tissue, tissue, juice, juice |
| CX3CL1/Fractalkine | + | + | = | 72, 73, 25 | tissue, tissue, juice | |
| CXCL8/IL-8 | + | + | = | 70, 71, 25 | juice, tissue, juice | |
| CX3CR1/Fractalkine-R | + | + | 74, 72 | tissue, tissue | ||
| CCL2/MCP-1 | + | = | 75, 25 | tissue, juice | ||
| TGF-β | + | = | 76, 71 | tissue, juice | ||
| TNF-α | + | = | 70, 25 | tissue, juice | ||
| IFN-γ | + | = | 70, 25 | tissue, juice | ||
| IL-1β | + | = | 70, 25 | tissue, juice | ||
| CCL5/Rantes | + | = | 77, 25 | tissue, juice | ||
| CCL4/MIP-1β | + | = | 77, 25 | tissue, juice | ||
| Annexin II | + | 78 | tissue | |||
| Artemin | + | 79 | tissue | |||
| CA19-9 | + | 80 | juice | |||
| CCR5 | + | 77 | tissue | |||
| CXCL11 | + | 77 | tissue | |||
| CXCL9 | + | 77 | tissue | |||
| CXCR3 | + | 77 | tissue | |||
| Decorin | + | 75 | tissue | |||
| GFRa3/Artemin-R | + | 79 | tissue | |||
| Glycoprotein Tenascin C | + | 78 | tissue | |||
| IL-12 | + | 70 | tissue | |||
| IL-1RAcP | + | 81 | tissue | |||
| IL-24 | + | 82 | tissue | |||
| IL-33 | + | 81 | tissue | |||
| MFG-E8/lactadherin | + | 73 | tissue | |||
| MIC-1 | + | 80 | tissue | |||
| LCN2/NGAL | + | 80 | tissue | |||
| Osteopontin | + | 83 | tissue | |||
| ST2L/IL1RL1 | + | 81 | tissue | |||
| CXCL10/IP10 | + | − | 77, 25 | tissue, juice | ||
| CCL3/MIP-1α | + | − | 77, 25 | tissue, juice | ||
| 14-3-3- zeta | = | 84 | tissue | |||
| CCL20/LARC/MIP3A | = | 84 | tissue | |||
| CD44 | = | 85 | tissue | |||
| bFGF/FGF2/FGF-β | = | 25 | juice | |||
| Flt-3L | = | 25 | juice | |||
| G-CSF | = | 25 | juice | |||
| GM-CSF | = | 25 | juice | |||
| GRO | = | 25 | juice | |||
| IAM1 | = | 25 | juice | |||
| IFN-α2 | = | 25 | juice | |||
| IL-10 | = | 25 | juice | |||
| IL-12p40 | = | 25 | juice | |||
| IL-12p70 | = | 25 | juice | |||
| IL-13 | = | 25 | juice | |||
| IL-17 | = | 25 | juice | |||
| IL-1Rα | = | 25 | juice | |||
| IL-2 | = | 25 | juice | |||
| IL-2Rα | = | 25 | juice | |||
| IL-4 | = | 25 | juice | |||
| IL-5 | = | 25 | juice | |||
| IL-7 | = | 25 | juice | |||
| IL-9 | = | 25 | juice | |||
| CCL7/MCP-3 | = | 25 | juice | |||
| CCL22/MDC | = | 25 | juice | |||
| sCD40L | = | 25 | juice | |||
| TGF-α | = | 25 | juice | |||
| TNF-β | = | 25 | juice | |||
| VEGF | = | 25 | juice | |||
| EGF | − | 25 | juice | |||
| Eotaxin | − | 25 | juice | |||
| IL-15 | − | 25 | juice | |||
| IL-1α | − | 25 | juice | |||
| IL-3 | − | 25 | juice | |||
| PDGF | − | 25 | juice | |||
The plus symbol (+) represents an increase in expression, the equal symbol (=) represents no significant difference, and the minus symbol (−) indicates a decrease in expression in CP patients compared to controls. Each individual symbol represents results from a single article, with the corresponding reference number listed to the right.